Skip to main navigationSkip to main content
The University of Southampton
Southampton Health Technology Assessments CentreNews

NICE issues guidance on canagliflozin in combination therapy for treating type 2 diabetes

Published: 2 July 2014

The National Institute for Health and Care Excellence (NICE) has issued guidance to the health service on the use of canagliflozin in combination therapy for the treatment of type 2 diabetes, based on a report produced by SHTAC.

NICE's guidance is that canagliflozin is recommended as a possible treatment taken with insulin, with or without other antidiabetic drugs.

Diabetes mellitus is a chronic metabolic disorder characterised by elevated blood glucose levels (hyperglycaemia) resulting from a lack of the hormone insulin or resistance to its action.  In the UK, about 90% of all adults with diabetes have type 2 diabetes. The UK prevalence of type 2 diabetes is rising because of increased prevalence of obesity, decreased physical activity and increased life expectancy after diagnosis because of better cardiovascular risk protection.

Canagliflozin (‘Invokana', Janssen-Cilag) is classed as a ‘selective sodium glucose-cotransporter 2' (SGLT-2) inhibitor which blocks the reabsorption of glucose in the kidneys and promotes excretion of excess glucose in the urine.

NICE's guidance is based on an evidence review group report prepared by SHTAC, which critically appraised the drug manufacturer's submission to NICE's Single Technology Appraisal process.

For more information on SHTAC's research into diabetes please visit our Research page.

Privacy Settings